Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JNJ

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

StockNews.com

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Benzinga

West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters

West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

5 Brand-Name Dividend Stocks to Grab Right Now

The stock market is expected to remain under pressure in the near term, given rising concerns over inflation, deepening supply chain disruptions, and the potential for aggressive central bank interest rate increases. For investors seeking ways to dodge market volatility and generate stable returns, we think it could be wise…

StockNews.com

AstraZeneca vs. Johnson & Johnson: Which Drug Manufacturer is a Better Buy?

The COVID-19 pandemic has boosted the revenues of most drug manufacturers. And since healthcare expenditure has been climbing steadily, and because the global population is aging, the demand for medicines is expected to grow. Quality drug manufacturers AstraZeneca (AZN) and Johnson & Johnson (JNJ) should benefit from this trend. But…

StockNews.com

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has observed the following analyst ratings within the last quarter:

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 21 strange trades.

Benzinga

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

StockNews.com

JNJ Regrets Paying For Controversial Prison Testing With Asbestos: Bloomberg

According to a Bloomberg News report, unsealed court documents show that Johnson & Johnson (NYSE:

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 28 strange trades.

Benzinga

Johnson & Johnson's COVID-19 Vaccine Less Effective Against Hospitalization, French Study Shows

According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine was about five times higher than those who received the Pfizer Inc (NYSE:

Benzinga

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Johnson & Johnson Allowed To Move Ahead With Bankruptcy Strategy On Talc Lawsuits: WSJ

In a federal bankruptcy court in Trenton, New Jersey, Judge Michael Kaplan ruled in favor of Johnson & Johnson's (NYSE: JNJ) controversial bankruptcy filing meant to settle 38,000 claims alleging its talc-based products caused cancer.

Benzinga

Johnson & Johnson Sees A Strong Move: Is It Ready For A Breakout?

Johnson & Johnson (NYSE: JNJ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible for th

Benzinga

Drug Distributors, JNJ Agree To Settle $26B Opioid Lawsuits

Distributors McKesson Corporation (NYSE: MCK), AmerisourceBergen Corp (NYSE: ABC), Cardinal Health Inc (NYSE: CAH

Benzinga

Johnson & Johnson Whale Trades For February 24

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 17 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Johnson & Johnson Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 20 strange trades.

Benzinga

Janssen's Tremfya Shows Clinical Response At 12 Weeks In Ulcerative Colitis

Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), has announced results from the

StockNews.com

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Benzinga

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a

Benzinga

Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection

Scientists have revealed data from their final analysis of Johnson & Johnson's (NYSE: JNJ) COVID-19 Phase 3 study, showing the vaccine may be even less effective in the longer term.

Benzinga

Johnson & Johnson Halts Production Of Its COVID-19 Vaccine: NYT

Johnson & Johnson (NYSE: JNJ) quietly shut down the only plant making usable batches of its COVID-19 vaccine, the

Benzinga

Hopeful Golden Cross Forms On Johnson & Johnson's Chart

If history is any guide, there may be good fortune ahead for shares of Johnson & Johnson (NYSE:JNJ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

1 … 11 12 13 14

People

Patrick Morrisey

60 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.